weight loss semaglutide vs tirzepatide Semaglutide vs. Tirzepatide for Weight

the deficiency of which is associated with the risk of contracting several diseases, notably cancer

This indication is approved for adults with a body mass index (BMI) of 30 kg/m or greater, or 27 kg/m or greater with at least one weight-related comorbidity

Hypoglycemia With Concomitant Use Of Insulin Secretagogues Or Insulin Patients receiving OZEMPIC in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia [see ADVERSE REACTIONS and DRUG INTERACTIONS ]

Many patients successfully switch from semaglutide to tirzepatide to restart their metabolic progress after hitting a sustained weight loss plateau